Eos SENOLYTIX Highlights PTC-2105 Preclinical Data at Obesity Forum
HOUSTON, Texas, June 5, 2026 Eos SENOLYTIX, Inc. presented new preclinical findings for its lead MitoXcelâ„¢ geropeptide candidate PTC-2105...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HOUSTON, Texas, June 5, 2026 Eos SENOLYTIX, Inc. presented new preclinical findings for its lead MitoXcelâ„¢ geropeptide candidate PTC-2105...
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
COPENHAGEN, Denmark, May 27, 2026 Zealand Pharma announced that new clinical data from its obesity and metabolic disease pipeline...
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayoâ„¢ (orforglipron), a first-in-class oral...
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
NEW TAIPEI CITY, Taiwan, Jan. 30, 2026 — Jyong Biotech announced updated Phase II clinical trial results for its...
Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...
